

WEST Search History

DATE: Friday, July 11, 2003

Set Name Query
side by side

Hit Count Set Name
result set

DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR

L11	L10 and (smooth muscle) and proliferat\$	12	L11
L10	L8 and (polyurethane? or silicone? or acrylate? or polyester? or (polyalkylene oxide?) or polyalcohol? or polyolefin? or (polyvinyl chloride?) or cellulose? or polyamide? or polyolefin? or (fluorinated polymer?))	17	L10
L9	L8 and biostable	1	L9
L8	L7 and (polyhydroxy\$ or polyanhydride? or polyphosphazene? or polyphosphorester? or polyorthocarbonate? or polyamide? or polyorthoester? or polyphosphoester? or polyorthocarbonate?)	17	L8
L7	L6 and biodegrad\$	24	L7
L6	L5 and (cerivastatin or atorvastatin or fluvastatin or lovastatin or pravastatin)	36	L6
L5	L4 and (sol or gel)	47	L5
L4	L3 and (polymer\$ or nonpolymer\$)	113	L4
L3	L2 and coat\$	129	L3
L2	L1 and stent	146	L2
L1	(HMG-CoA) and inhibit\$	2918	L1

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau153cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3	Feb 24 PCTGEN now available on STN
NEWS	4	Feb 24 TEMA now available on STN
NEWS	5	Feb 26 NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26 PCTFULL now contains images
NEWS	7	Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24 PATDPAFULL now available on STN
NEWS	9	Mar 24 Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr. 11 Display formats in DGENE enhanced
NEWS	11	Apr 14 MEDLINE Reload
NEWS	12	Apr 17 Polymer searching in REGISTRY enhanced
NEWS	13	Jun 13 Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	14	Apr 21 New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28 RDISCLOSURE now available on STN
NEWS	16	May 05 Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	19	May 19 Simultaneous left and right truncation added to WSCA
NEWS	20	May 19 RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06 Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06 PASCAL enhanced with additional data
NEWS	23	Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25 HSDB has been reloaded
NEWS EXPRESS		April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:01:39 ON 11 JUL 2003

=> file caplus uspatful europatful japio medline biosis embase		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'CAPLUS' ENTERED AT 11:02:52 ON 11 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 11:02:52 ON 11 JUL 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 11:02:52 ON 11 JUL 2003
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 11:02:52 ON 11 JUL 2003
COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 11:02:52 ON 11 JUL 2003

FILE 'BIOSIS' ENTERED AT 11:02:52 ON 11 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 11:02:52 ON 11 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

=> s (HMG-COA) and inhibit?
L1 17156 (HMG-COA) AND INHIBIT?

=> s l1 and stent
L2 183 L1 AND STENT

=> s l2 and coat?
L3 134 L2 AND COAT?

=> s l3 and (polymer or nonpolymer)
) IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l3 and (polymer or nonpolymer)
L4 113 L3 AND (POLYMER OR NONPOLYMER)

=> s l4 and (sol or gel)
L5 41 L4 AND (SOL OR GEL)

=> s l5 and (cerivastatin or atorvastatin or fluvastatin or lovastatin or pravastatin)
L6 26 L5 AND (CERIVASTATIN OR ATORVASTATIN OR FLUVASTATIN OR LOVASTATIN OR PRAVASTATIN)

=> s l6 and biodegrad

=> s 16 and biodegrad
=> d his

(FILE 'HOME' ENTERED AT 11:01:39 ON 11 JUL 2003)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
ENTERED AT 11:02:52 ON 11 JUL 2003

L1 17156 S (HMG-COA) AND INHIBIT?
L2 183 S L1 AND STENT
L3 134 S L2 AND COAT?
L4 113 S L3 AND (POLYMER OR NONPOLYMER)
L5 41 S L4 AND (SOL OR GEL)
L6 26 S L5 AND (CERIVASTATIN OR ATORVASTATIN OR FLUVASTATIN OR LOVAS

=> s 16 and biodegrad?
L7 18 L6 AND BIODEGRAD?

=> s 17 and (polyhydroxy? or polyanhydride# or polyphosphazene# or polyphosphoester#
or polyorthocarbonate# or polyamide# or polyorthoester# or polyphosphoester# or
polyorthocarbonate#)

L8 13 L7 AND (POLYHYDROXY? OR POLYANHYDRIDE# OR POLYPHOSPHAZENE# OR
POLYPHOPHOESTER# OR POLYORTHOCARBONATE# OR POLYAMIDE# OR POLYORT
HOESTER# OR POLYPHOSPHOESTER# OR POLYORTHOCARBONATE#)

=> s 18 and (polyurethane# or silicone# or acrylate# or polyester# or
(polyalkylene oxide#) or polyalcohol# or polyolefin# or (polyvinyl chloride#) or
cellulose# or polyamide# or (fluorinated polymer#))

3 FILES SEARCHED...

L9 13 L8 AND (POLYURETHANE# OR SILICONE# OR ACRYLATE# OR POLYESTESTER
OR (POLYALKYLENE OXDE#) OR POLYALCOHOL# OR POLYOLEFIN# OR
(POLYVINYL CHLORIDE#) OR CELLULOSE# OR POLYAMIDE# OR (FLUORINATE
D POLYMER#))

=> s 19 and ((smooth muscle) and proliferat?)

4 FILES SEARCHED...

L10 9 L9 AND ((SMOOTH MUSCLE) AND PROLIFERAT?)

=> d 19 1-10 ibib abs

L9 ANSWER 1 OF 13 USPATFULL

ACCESSION NUMBER: 2003:173192 USPATFULL

TITLE: Methods of using 48149, a human aminopeptidase family
member

INVENTOR(S): Chun, Miyoung, Belmont, MA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119036	A1	20030626
APPLICATION INFO.:	US 2002-281904	A1	20021028 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-335084P	20011031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Steven A. Bossone, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	5695	

AB Isolated nucleic acids molecules, designated 48149 nucleic acid molecules, which encode human Aminopeptidase N, are disclosed. The invention provides methods of modulating 48149 activity, which is associated with the formation of atherosclerotic lesions in blood vessels. The invention further provides methods of treating, preventing and diagnosing cardiovascular disorders such as atherosclerosis, as well as disorders associated with the metabolism of lipids, for example, in the liver.

L9 ANSWER 2 OF 13 USPATFULL

ACCESSION NUMBER: 2003:159431 USPATFULL
TITLE: Methods of using 279, a human G protein-coupled protein receptor
INVENTOR(S): Logan, Thomas Joseph, Needham, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003109044	A1	20030612
APPLICATION INFO.:	US 2002-267811	A1	20021009 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-329648P	20011016 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	5366	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 279 nucleic acid molecules, which encode human G protein-coupled receptor (GPCR) family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 279 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 279 gene has been introduced or disrupted. The invention still further provides isolated 279 proteins, fusion proteins, antigenic peptides and anti-279 antibodies. Methods utilizing compositions of the invention to treat, prevent or diagnose angiogenic disorders, e.g., cardiovascular and cancerous disorders, are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 13 USPATFULL

ACCESSION NUMBER: 2003:140464 USPATFULL
TITLE: Novel human membrane-associated protein and cell surface protein family members
INVENTOR(S): Meyers, Rachel E., Newton, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Curtis, Rory A. J., Framingham, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Leiby, Kevin R., Natick, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003096305	A1	20030522
APPLICATION INFO.:	US 2002-162435	A1	20020604 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-836499, filed on 17 Apr 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-US12420	20010417
	WO 2001-US19963	20010625
	WO 2001-US16013	20010518
	WO 2001-US20055	20010621
	WO 2002-US275	20020108
	WO 2001-US41811	20010821
	US 2000-197507P	20000418 (60)
	US 2000-214220P	20000623 (60)
	US 2000-205674P	20000519 (60)
	US 2000-213963P	20000623 (60)
	US 2001-260286P	20010108 (60)
	US 2000-226612P	20000821 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804

NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 30445

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 16051a, 16051b, 58199, 57805, 56739, 39362, and 23228 nucleic acid molecules, which encode novel human membrane-associated protein family members, and human cell surface protein family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 gene has been introduced or disrupted. The invention still further provides isolated 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 proteins, fusion proteins; antigenic peptides and anti-16051a, 16051b, 58199, 57805, 56739, 39362, or 23228 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 13 USPATFULL
ACCESSION NUMBER: 2003:133526 USPATFULL
TITLE: Devices and compounds for treating arterial restenosis
INVENTOR(S): Zahradka, Peter, Winnipeg, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003091611	A1	20030515
APPLICATION INFO.:	US 2002-273103	A1	20021016 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-585886, filed on 31 May 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-150696P	19990602 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Nicholas S. Buffinger, Morrison & Foerster LLP, 755
Page Mill Road, Palo Alto, CA, 94304-1018
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Page(s)
LINE COUNT: 2051

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described herein is the use of ADPRT decoy substrates to treat or prevent proliferative disorders. In one example, MIBG is shown to prevent restenosis in damaged vessels. In one embodiment, MIBG is combined with an adhesive agent for localizing the mixture to the site of injury. As a result of this arrangement, MIBG is not systemically released.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 13 USPATFULL

ACCESSION NUMBER: 2003:120257 USPATFULL
TITLE: 1983, 52881, 2398, 45449, 50289, and 52872, novel G protein-coupled receptors and uses therefor
INVENTOR(S): Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., a Delaware corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003082738	A1	20030501
APPLICATION INFO.:	US 2002-282837	A1	20021029 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-796338, filed on 28 Feb 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-186059P	20000229 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	49 Drawing Page(s)	
LINE COUNT:	8096	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 1983, 52881, 2398, 45449, 50289, and 52872 nucleic acid molecules, which encode novel G protein-coupled receptor members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 1983, 52881, 2398, 45449, 50289, or 52872 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 1983, 52881, 2398, 45449, 50289, or 52872 gene has been introduced or disrupted. The invention still further provides isolated 1983, 52881, 2398, 45449, 50289, or 52872 proteins, fusion proteins, antigenic peptides and anti-1983, 52881, 2398, 45449, 50289, or 52872 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 13 USPATFULL

ACCESSION NUMBER: 2003:112580 USPATFULL

TITLE: **Stent coatings** containing
HMG-CoA reductase **inhibitors**

INVENTOR(S): Pathak, Chandrashekhar, Austin, TX, UNITED STATES
Akella, Rama, Austin, TX, UNITED STATES
Ranieri, John, Atlanta, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003077310	A1	20030424
APPLICATION INFO.:	US 2001-991235	A1	20011022 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SULZER MEDICA USA INC., Suite 1600, 3 East Greenway Plaza, Houston, TX, 77046		
NUMBER OF CLAIMS:	41		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	962		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Stents with **coatings** comprising a combination of a restenosis **inhibitor** comprising an **HMG-CoA** reductase **inhibitor** and a carrier. Also provided are methods of **coating** stents with a combination of an **HMG-CoA** reductase **inhibitor** and a carrier. A preferred example of a restenosis **inhibitor** is **cerivastatin**. The **stent coatings** have been shown to release restenosis **inhibitors** in their active forms.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 13 USPATFULL

ACCESSION NUMBER: 2003:95829 USPATFULL

TITLE: Devices and compounds for treating arterial restenosis

INVENTOR(S): Zahradka, Peter, Winnipeg, CANADA

PATENT ASSIGNEE(S): Cardiovascular Solutions, Inc., Winnipeg, CANADA
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6544541	B1	20030408
APPLICATION INFO.:	US 2000-585886		20000531 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-150696P	19990602 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Bennett, Rachel M.	
LEGAL REPRESENTATIVE:	Morrison & Foerster LLP	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	32 Drawing Figure(s); 34 Drawing Page(s)	
LINE COUNT:	2271	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described herein is the use of ADPRT decoy substrates to treat or prevent proliferative disorders. In one example, MIBG is shown to prevent restenosis in damaged vessels. In one embodiment, MIBG is

combined with an adhesive agent for localizing the mixture to the site of injury. As a result of this arrangement, MIBG is not systemically released.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 13 USPATFULL

ACCESSION NUMBER: 2002:294662 USPATFULL
TITLE: 39362, a novel human CUB domain-containing protein family member and uses thereof
INVENTOR(S): Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002164705	A1	20021107
APPLICATION INFO.:	US 2002-41406	A1	20020108 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-260286P	20010108 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	5546	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 39362 nucleic acid molecules, which encode novel CUB domain-containing protein members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 39362 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 39362 gene has been introduced or disrupted. The invention still further provides isolated 39362 proteins, fusion proteins, antigenic peptides and anti-39362 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 13 USPATFULL

ACCESSION NUMBER: 2002:171640 USPATFULL
TITLE: Intravascular drug delivery device and use therefor
INVENTOR(S): Humes, H. David, Ann Arbor, MI, UNITED STATES
Tziampazis, Evangelos, Plymouth, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002090388	A1	20020711
APPLICATION INFO.:	US 2001-999210	A1	20011130 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-250746P	20001201 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TESTA, HURWITZ & THIBEAULT, LLP, HIGH STREET TOWER, 125 HIGH STREET, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 9 Drawing Page(s)

LINE COUNT: 1905

AB Disclosed is an implantable drug delivery device for delivering a pre-selected drug directly into the systemic circulation of an animal. The device comprises an anchor immobilizable to an inner wall of an intact blood vessel. The device also comprises a drug containing reservoir that is retained in place within the blood vessel by the immobilized anchor. The reservoir may include, for example, a drug containing osmotic pump or a drug permeable capsule having disposed therein drug containing particles, which release the drug directly into blood passing the reservoir. The invention also provides a minimally invasive method for introducing into a blood vessel and, optionally, removing from the blood vessel the drug delivery device of the invention.

L9 ANSWER 10 OF 13 USPATFULL

ACCESSION NUMBER: 2002:157616 USPATFULL

TITLE: Lipid-based nitric oxide donors

INVENTOR(S): Herrmann, Robert A., Boston, MA, UNITED STATES

Naimark, Wendy, Cambridge, MA, UNITED STATES

PATENT ASSIGNEE(S): Scimed Life Systems, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002082221	A1	20020627
APPLICATION INFO.:	US 2000-745226	A1	20001221 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Mayer, Fortkort & Williams, L.L.C., Suite 250, 200 Executive Drive, West Orange, NJ, 07052		
NUMBER OF CLAIMS:	57		
EXEMPLARY CLAIM:	1		
LINE COUNT:	963		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel nitric-oxide releasing lipid molecules are provided which comprise a lipid molecule selected from (a) phosphoglycerides, (b) lipids having a sphingosine base as a backbone, (c) monoacylglycerols, (d) diacylglycerols, (e) glycosylacylglycerols, and (f) sterol compounds of the formula: ##STR1##

where R is a branched aliphatic chain of eight or more carbon atoms, wherein the lipid molecule is provided with a nitric-oxide containing group which comprises (a) a--S--N.dbd.O moiety, (b) a--O--N.dbd.O moiety, or (c) a ##STR2##

moiety. Also provided are methods of forming such nitric oxide releasing lipid molecules.

Various pharmaceutical compositions, topical liquids and drug delivery systems comprising the nitric-oxide releasing lipid molecules are also described. Further provided are methods for therapeutically administering nitric oxide to patients, methods of treating or preventing various conditions, methods for promoting wound healing and methods of reducing the cells present in an atherosclerotic lesion, which methods utilize the nitric-oxide releasing lipid molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.